Zhou D - Search Results

1

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK. Proia DA, et al. Among authors: zhou d. PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552. PLoS One. 2011. PMID: 21533169 Free PMC article.

2

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K. Ying W, et al. Among authors: zhou d. Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5. Mol Cancer Ther. 2012. PMID: 22144665

3

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.

Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y. Proia DA, et al. Among authors: zhou d. Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10. Invest New Drugs. 2012. PMID: 22227828 Free PMC article.

4

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

Liu Y, Ye J, Shin Ogawa L, Inoue T, Huang Q, Chu J, Bates RC, Ying W, Sonderfan AJ, Rao PE, Zhou D. Liu Y, et al. Among authors: zhou d. PLoS One. 2015 May 14;10(5):e0127361. doi: 10.1371/journal.pone.0127361. eCollection 2015. PLoS One. 2015. PMID: 25974040 Free PMC article.

5

The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.

Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J, Sonderfan AJ. Foley KP, et al. Among authors: zhou d. J Pharmacol Exp Ther. 2012 Nov;343(2):529-38. doi: 10.1124/jpet.112.196873. Epub 2012 Jul 26. J Pharmacol Exp Ther. 2012. PMID: 22837008

6

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ. Zhou D, et al. Toxicol Appl Pharmacol. 2013 Dec 1;273(2):401-9. doi: 10.1016/j.taap.2013.09.018. Epub 2013 Oct 1. Toxicol Appl Pharmacol. 2013. PMID: 24090817 Free article.

7

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.

Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, Li L, Wu Y, Qin J, Balasubramanyam V, Barsoum J, Ono M. Wada Y, et al. Among authors: zhou d. Blood. 2007 Feb 1;109(3):1156-64. doi: 10.1182/blood-2006-04-019398. Epub 2006 Oct 19. Blood. 2007. PMID: 17053051 Free article.

8

Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

Chen S, Sun L, Koya K, Tatsuta N, Xia Z, Korbut T, Du Z, Wu J, Liang G, Jiang J, Ono M, Zhou D, Sonderfan A. Chen S, et al. Among authors: zhou d. Bioorg Med Chem Lett. 2013 Sep 15;23(18):5070-6. doi: 10.1016/j.bmcl.2013.07.032. Epub 2013 Jul 25. Bioorg Med Chem Lett. 2013. PMID: 23937981

9

Dynamic Changes of Late-Onset Cystic Brain Radionecrosis.

Abdulaziz AT, Chen L, He L, Zhou D. Abdulaziz AT, et al. Among authors: zhou d. Neurology. 2025 Feb 25;104(4):e210118. doi: 10.1212/WNL.0000000000210118. Epub 2025 Jan 17. Neurology. 2025. PMID: 39823545 No abstract available.

10

Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.

Abegesah A, Oh DY, Lim K, Fan C, Chen C, Kim C, Wang J, Xynos I, Zotkiewicz M, Ren S, Phipps A, Gibbs M, Zhou D. Abegesah A, et al. Among authors: zhou d. Cancer Chemother Pharmacol. 2025 Jan 17;95(1):23. doi: 10.1007/s00280-024-04743-8. Cancer Chemother Pharmacol. 2025. PMID: 39821700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,367 results

Search Page

Filters